CAS 330784-47-9 Male Sex Hormones Injectable Anabolic Steriod Avanafil for Treating Impotence

Avanafil Applications:

Avanafil is a PDE5 inhibitor approved for erectile dysfunction by FDA on April 27, 2012 and by EMA on June 21, 2013. Avanafil is known by the trademark names Stendra and Spedra and was developed by Vivus Inc.
Avanafil acts by inhibiting a specific phosphodiesterase type 5 enzyme which is found in various body tissues, but primarily in the corpus cavernosum penis, as well as the retina. Other similar drugs are sildenafil, tadalafil and vardenafil. The advantage of avanafil is that it has very fast onset of action compared with other PDE5 inhibitors. It is absorbed quickly, reaching a maximum concentration in about 30-45 minutes. About two-thirds of the participants were able to engage in sexual activity within 15 minutes.
 

Functions:

Tadalafil is an oral selective pde5 inhibitor indicated for the treatment of erection dysfunction. The average of effective time is 16 minutes. The plasma concentration can reach peak after two hours, the half-life is 18~48hours. Even is five days, the purity of can be tested in blood. The clinical report shows that it can be up to 83% after taking, and the dosage is 25-35mg. The main advantages are little side-effect, lasting for a long time and working strongly in two or three days.